609 Followers on Owler

CytomX

 is an early-stage biotechnology company that develops antibody based therapeutics for the treatment of cancer and inflammatory diseases... Read more
OverviewCompetitorsAcquisitionsFundingNews & Insights

CytomX

 is an early-stage biotechnology company that develops antibody based therapeutics for the treatment of cancer and inflammatory diseases... Read more
CytomX Chairman & CEO: Sean A. McCarthy

Chairman & CEO

Sean A. McCarthy

CEO Approval Rating

88/100

2008

PublicIndependent CompanyNASDAQCTMX

Pharmaceuticals & Biotechnology
Biotechnology
2836 NAICS listing

Annual Revenue
$138.1M
Employees
170
Funding
$320.6M
Acquisitions
1

News

Conference Presentation
Mar 05, 2025
Marketscreener
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
Layoffs
Jan 07, 2025
BioSpace
CytomX to Cut 40% of Staff as It Updates Pipeline Priorities

CytomX Competitors

1ADC Therapeutics
2ADC Bio
3Meditope
4ImmunGene
5Igenica
6Cara Therapeutics
7BeiGene
8BioAtla
9Rigel Pharmaceuticals
10Principia Biopharma, Inc.
Unlock 12 + competitors

Trending Companies